TICKERNOMICS Sign up
Last Update: 2023-12-23 06:02:58
Incannex Healthcare Ltd ( IXHL ) https://www.incannex.com.au
3.74USD
Sector:
Healthcare
Industry:
Drug Manufacturers-Specialty & Generic
Country:
Australia
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
IXHL
37.50%
SPY
30.72%
IXHL
0.00%
SPY
112.82%
IXHL
0.00%
SPY
201.04%
IXHL
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
178.20
178.19
0.01
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-17.25
167.73
2.12
-16.61
0.00
-17.98
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-56436.17
-24.21
-55709.79
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-25.74
-25.72
0.00
Other Earnings and Cash Flow Stats:
Incannex Healthcare Ltd ( IXHL ) Net Income TTM ($MM) is -10.65
Incannex Healthcare Ltd ( IXHL ) Operating Income TTM ($MM) is -10.49
Incannex Healthcare Ltd ( IXHL ) Owners' Earnings Annual ($MM) is 0.00
Incannex Healthcare Ltd ( IXHL ) Current Price to Owners' Earnings ratio is 0.00
Incannex Healthcare Ltd ( IXHL ) EBITDA TTM ($MM) is -10.55
Incannex Healthcare Ltd ( IXHL ) EBITDA Margin is -55709.79%
Capital Allocation:
Incannex Healthcare Ltd ( IXHL ) has paid 0.00 dividends per share and bought back 0.0 million shares in the past 12 months
Incannex Healthcare Ltd ( IXHL ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Incannex Healthcare Ltd ( IXHL ) Interest-bearing Debt ($MM) as of last quarter is 0
Incannex Healthcare Ltd ( IXHL ) Annual Working Capital Investments ($MM) are -1
Incannex Healthcare Ltd ( IXHL ) Book Value ($MM) as of last quarter is 84
Incannex Healthcare Ltd ( IXHL ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Incannex Healthcare Ltd ( IXHL ) has 33 million in cash on hand as of last quarter
Incannex Healthcare Ltd ( IXHL ) has 3 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Incannex Healthcare Ltd ( IXHL ) has 47 common shares outstanding as of last quarter
Incannex Healthcare Ltd ( IXHL ) has 0 million USD of preferred stock value
Academic Scores:
Incannex Healthcare Ltd ( IXHL ) Altman Z-Score is 22.77 as of last quarter
Incannex Healthcare Ltd ( IXHL ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Incannex Healthcare Ltd ( IXHL ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Incannex Healthcare Ltd ( IXHL ) for the amount of $ on
6.98% of Incannex Healthcare Ltd ( IXHL ) is held by insiders, and 2.30% is held by institutions
Incannex Healthcare Ltd ( IXHL ) went public on 2022-03-02
Other Incannex Healthcare Ltd ( IXHL ) financial metrics:
FCF:-9.32
Unlevered Free Cash Flow:0.00
EPS:-0.21
Operating Margin:-56436.17
Gross Profit Margin:-24.21
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-18.17
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Incannex Healthcare Ltd ( IXHL ) :
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury/concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Melbourne, Australia.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.